Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped Due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: An Exploratory Analysis...
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J
. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatol Res. 2022; 52(5):462-470.
DOI: 10.1111/hepr.13748.
View
2.
Han J, Jang J
. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2023; 24(14).
PMC: 10380709.
DOI: 10.3390/ijms241411799.
View
3.
Kudo M, Tsuchiya K, Shao Y, Finn R, Galle P, Ducreux M
. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2024; 13(4):401-412.
PMC: 11305667.
DOI: 10.1159/000535501.
View
4.
Hatanaka T, Hiraoka A, Tada T, Kakizaki S
. Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase.... Liver Cancer. 2024; 13(6):669-670.
PMC: 11649253.
DOI: 10.1159/000538580.
View